The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.

Stewart CE, French KP, Wright TJ, Wilhoit K, Randolph KM, Danesi CP, Gilkison CR, Karmonik C, Lu L, Dillon EL, Durham WJ, Urban RJ, Sheffield-Moore M, Masel BE

eNeurologicalSci17 Jun 2026

PMID42382101PMCIDPMC13316082DOI10.1016/j.ensci.2026.100616PepBankPUB-42382101

Read at source PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with normal cognition to mild cognitive impairment, low-dose tesamorelin did not significantly change body composition versus placebo.
In plain wordsIn adults with normal thinking to mild impairment, low-dose tesamorelin did not clearly change body composition compared with placebo.
Peptide
Tesamorelin
Outcome
No significant changeBody composition
Study
n = 22
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
1 mg · 10 weeksAs given in this study (human).
Source sentences
Summary
Low-dose GHRH treatment was not directly linked with significant changes in study measures.
2 context sentences(design, population, supporting numbers)
Summary · context
body composition
Summary · context
In a double-blind, placebo-controlled pilot trial, we assessed 22 subjects with baseline cognition ranging from normal cognition to mild cognitive impairment before and after 10 weeks of treatment with low-dose tesamorelin (1 mg; GHRH analog) or placebo.
Report a problemFND-4238210101
02HumanRandomized controlled trialEfficacy outcome
In adults with normal cognition to mild cognitive impairment, low-dose tesamorelin did not significantly change fatigue versus placebo.
In plain wordsIn adults with normal thinking to mild impairment, low-dose tesamorelin did not clearly change tiredness compared with placebo.
Peptide
Tesamorelin
Outcome
No significant changeFatigue
Study
n = 22
Comparator
Placebo
Outcome group
Exercise and physical function · Whole body
Studied dose
1 mg · 10 weeksAs given in this study (human).
Source sentences
Summary
Low-dose GHRH treatment was not directly linked with significant changes in study measures.
2 context sentences(design, population, supporting numbers)
Summary · context
fatigue
Summary · context
In a double-blind, placebo-controlled pilot trial, we assessed 22 subjects with baseline cognition ranging from normal cognition to mild cognitive impairment before and after 10 weeks of treatment with low-dose tesamorelin (1 mg; GHRH analog) or placebo.
Report a problemFND-4238210102
03HumanRandomized controlled trialEfficacy outcome
In adults with normal cognition to mild cognitive impairment, low-dose tesamorelin did not significantly change sleep versus placebo.
In plain wordsIn adults with normal thinking to mild impairment, low-dose tesamorelin did not clearly change sleep compared with placebo.
Peptide
Tesamorelin
Outcome
No significant changeSleep
Study
n = 22
Comparator
Placebo
Outcome group
Sleep · Sleep
Studied dose
1 mg · 10 weeksAs given in this study (human).
Source sentences
Summary
Low-dose GHRH treatment was not directly linked with significant changes in study measures.
2 context sentences(design, population, supporting numbers)
Summary · context
sleep
Summary · context
In a double-blind, placebo-controlled pilot trial, we assessed 22 subjects with baseline cognition ranging from normal cognition to mild cognitive impairment before and after 10 weeks of treatment with low-dose tesamorelin (1 mg; GHRH analog) or placebo.
Report a problemFND-4238210103
04HumanRandomized controlled trialEfficacy outcome
In adults with normal cognition to mild cognitive impairment, low-dose tesamorelin did not significantly change physical performance versus placebo.
In plain wordsIn adults with normal thinking to mild impairment, low-dose tesamorelin did not clearly change physical performance compared with placebo.
Peptide
Tesamorelin
Outcome
No significant changePhysical performance
Study
n = 22
Comparator
Placebo
Outcome group
Exercise and physical function · Whole body
Studied dose
1 mg · 10 weeksAs given in this study (human).
Source sentences
Summary
Low-dose GHRH treatment was not directly linked with significant changes in study measures.
2 context sentences(design, population, supporting numbers)
Summary · context
physical performance
Summary · context
In a double-blind, placebo-controlled pilot trial, we assessed 22 subjects with baseline cognition ranging from normal cognition to mild cognitive impairment before and after 10 weeks of treatment with low-dose tesamorelin (1 mg; GHRH analog) or placebo.
Report a problemFND-4238210104
05HumanRandomized controlled trialEfficacy outcome
In adults with normal cognition to mild cognitive impairment, low-dose tesamorelin did not significantly change glucose tolerance versus placebo.
In plain wordsIn adults with normal thinking to mild impairment, low-dose tesamorelin did not clearly change glucose tolerance compared with placebo.
Peptide
Tesamorelin
Outcome
No significant changeGlucose tolerance
Study
n = 22
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1 mg · 10 weeksAs given in this study (human).
Source sentences
Summary
Low-dose GHRH treatment was not directly linked with significant changes in study measures.
2 context sentences(design, population, supporting numbers)
Summary · context
glucose tolerance
Summary · context
In a double-blind, placebo-controlled pilot trial, we assessed 22 subjects with baseline cognition ranging from normal cognition to mild cognitive impairment before and after 10 weeks of treatment with low-dose tesamorelin (1 mg; GHRH analog) or placebo.
Report a problemFND-4238210105
06HumanRandomized controlled trialEfficacy outcome
In adults with normal cognition to mild cognitive impairment, low-dose tesamorelin did not significantly change cognitive function versus placebo.
In plain wordsIn adults with normal thinking to mild impairment, low-dose tesamorelin did not clearly change thinking test results compared with placebo.
Peptide
Tesamorelin
Outcome
No significant changeCognitive function
Study
n = 22
Comparator
Placebo
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
1 mg · 10 weeksAs given in this study (human).
Source sentences
Summary
Low-dose GHRH treatment was not directly linked with significant changes in study measures.
2 context sentences(design, population, supporting numbers)
Summary · context
cognitive function
Summary · context
In a double-blind, placebo-controlled pilot trial, we assessed 22 subjects with baseline cognition ranging from normal cognition to mild cognitive impairment before and after 10 weeks of treatment with low-dose tesamorelin (1 mg; GHRH analog) or placebo.
Report a problemFND-4238210106
07HumanRandomized controlled trialEfficacy outcome
In adults with normal cognition to mild cognitive impairment, low-dose tesamorelin did not significantly change brain morphometry or functional connectivity versus placebo.
In plain wordsIn adults with normal thinking to mild impairment, low-dose tesamorelin did not clearly change brain structure or connectivity compared with placebo.
Peptide
Tesamorelin
Outcome
No significant changeBrain morphometry and functional connectivity
Study
n = 22
Comparator
Placebo
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
1 mg · 10 weeksAs given in this study (human).
Source sentences
Summary
Low-dose GHRH treatment was not directly linked with significant changes in study measures.
2 context sentences(design, population, supporting numbers)
Summary · context
brain morphometry and functional connectivity.
Summary · context
In a double-blind, placebo-controlled pilot trial, we assessed 22 subjects with baseline cognition ranging from normal cognition to mild cognitive impairment before and after 10 weeks of treatment with low-dose tesamorelin (1 mg; GHRH analog) or placebo.
Report a problemFND-4238210107
08HumanRandomized controlled trialEfficacy outcome
In an exploratory machine-learning analysis, tesamorelin was potentially linked with differences in brain areas related to cognitive function, including the right anterior cingulate and left superior frontal occipital fasciculus.
In plain wordsA computer analysis found possible tesamorelin-linked differences in brain areas tied to thinking. The finding is preliminary.
Peptide
Tesamorelin
Outcome
Direction not reportedMachine-learning brain region differences
Study
n = 22
Comparator
Placebo
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
1 mg · 10 weeksAs given in this study (human).
Source sentences
Summary
Using advanced machine learning (ML) models to further examine the data we identified potential treatment-related differences in areas of the brain related to cognitive function including the right anterior cingulate and left superior frontal occipital fasciculus.
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blind, placebo-controlled pilot trial, we assessed 22 subjects with baseline cognition ranging from normal cognition to mild cognitive impairment before and after 10 weeks of treatment with low-dose tesamorelin (1 mg; GHRH analog) or placebo.
Report a problemFND-4238210108

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT02553603

The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment

The University of Texas Medical Branch, Galvestonn = 2218 Jul 2017 to 17 Jan 2019

Mild Cognitive Impairment

Trial page ClinicalTrials.govUpdated 4 Nov 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.